CandlesenseCandlesense
News/Companies/XOMA

XOMA News

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

XOMA

(NASDAQ:XOMA) EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference.

September 3, 2025Investor Update
Read more →

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

XOMA

Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announced acquisition of LAVA Therapeutics.

August 13, 2025M&A
Read more →

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

XOMA

XOMA Royalty closes tender offer for Turnstone Biologics.

August 11, 2025Mergers
Read more →

HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $104 Price Target

XOMA

May 28, 2025
Read more →

XOMA Royalty Purchases Future Mezagitamab Royalty And Milestone Interests Held By BioInvent For $20M At Closing, With Total Transaction Of Up To $30M

XOMA

May 27, 2025
Read more →

Benchmark Initiates Coverage On XOMA Royalty with Buy Rating, Announces Price Target of $35

XOMA

April 17, 2025
Read more →

The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts

XOMA

March 28, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $104 Price Target

XOMA

March 28, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $104 Price Target

XOMA

March 19, 2025
Read more →

XOMA Q4 2024 GAAP EPS $(0.45) Misses $(0.30) Estimate, Sales $8.71M Miss $8.75M Estimate

XOMA

March 17, 2025
Read more →